Sosei Group (4565 JP): Q1 FY12/26 flash update
Revenue increased to JPY11.3bn (+69.4% YoY), driven by milestone achievements, while R&D expenses decreased by 20.5% YoY. Core operating...
120 Views
Primer: Sosei Group (4565 JP) - Apr 2026
Sosei Group, which has rebranded to Nxera Pharma as of April 2024, is a technology-driven biopharmaceutical company with a world-leading...
121 Views
APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear
Sino Bio got fourth indication approval for Benmelstobart plus Anlotinib. Wuxi Biologics’ three facilities got Korean GMP certification. FDA...
320 Views
Sosei Group (4565 JP): Q3 FY12/25 flash update
Revenue decreased by JPY135mn to JPY21.8bn due to smaller milestone payments, partially offset by Quviviq sales. R&D expenses rose 31.5% YoY...
485 Views
APAC Healthcare Weekly (April 19) – Fosun Pharma, Remegen, Daiichi Sankyo, Astellas Pharma, Telix
FDA granted Priority Review to Daiichi Sankyo’s I-DXd. Astellas Pharma initiates Phase 3 study for setidegrasib. Telix and Regeneron...
415 Views